Here we go. Reason 1 to love the God Molecule - This one from Jesspro on iHub.
Ariad's probable advantage with the New molecule is that, during clinical trials, its performance will likely be compared to placebos as there - this because there are no current treatments for "unmet medical needs," which is how Ariad has described the purpose of this new molecule. As a result, even a modest advantage in the trials over placebos maybe considered successful. Furthermore, once P1 and P2 have been completed, and if they are successful, accelerated approval could follow. Unlike 113 and pona(CML), which had to compete with existing therapies, the Nmole development may not be as expensive and could advance more quickly.
Note: The following is from Kendra at Ariad IR regarding the God Molecule
|
Sep 30
 | | ||
We have communicated that we expect to nominate our next development candidate by year-end.
Regards,
Kendra
HB confirmed this at Stifel conf. last week, minute 24:30. "We are on track to designate our next development candidate by year end". http://www.veracast.com/webcasts/stifel/healthcare2014/48104468024.cfm
ReplyDeleteTHEY CAN NOT HANDLE THE TRUTH ON STOCK TWITS I SEE..LOLing..GREAT JOB TC
ReplyDelete